MedTrace Logo

Safety and Efficacy Study of Vaginal Misoprostol for Cervical Ripening and Induction of Labor

NCT01428037 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2013-11-25

No results posted yet for this study

Summary

The purpose of this study is to estimate the efficacy and safety of the 25mcg vaginal misoprostol for cervical ripening and induction of labour.

Conditions

  • Cervical Ripening
  • Induction of Labor

Interventions

DRUG

Placebo

One tablet vaginal inserted at 4 hrly interval with maximum of three doses

DRUG

Misoprostol vaginal Tablet 25 mcg

One tablet vaginal insert at 4 hrly interval with maximum of three doses

Sponsors & Collaborators

  • Regenex Pharmaceutical, China

    lead OTHER

Principal Investigators

  • Wen Di, MD · RenJi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01428037 on ClinicalTrials.gov